BOXED WARNING Not for treatment of obesity or weight loss; doses beyond daily hormonal requirements may cause serious or life-threatening toxicity, esp. with sympathomimetic amines.
FDA dosing
Population
Start
Target
Max
Hypothyroidism
Adults
25 mcg QD
25–75 mcg QD (maintenance)
Hypothyroidism
Elderly or underlying cardiac disease
5 mcg QD, increase in 5 mcg increments
Titrate to euthyroid
Hypothyroidism
Pediatric
5 mcg QD (infants ~20 mcg QD; ~50 mcg QD at 1 yr; adult dose >3 yr)
Titrate to euthyroid
Thyroid suppression test
Adults
75–100 mcg QD for 7 days
TSH suppression in well-differentiated thyroid cancer
Adults
Dose targeted to desired TSH suppression
Titration Adults: increase 25 mcg every 1–2 weeks; elderly/cardiac: 5 mcg increments; pediatric: 5 mcg every 3–4 days.
Renal Undefined
Hepatic Undefined
Narrow therapeutic index; rapid onset of action.
Instructions
Administer orally once daily.
When switching from levothyroxine: discontinue levothyroxine and start liothyronine at a low dose, titrating up (residual T4 effects persist several weeks).
Return to pre-pregnancy dose immediately after delivery.
Contraindications
Uncorrected adrenal (cortical) insufficiency
Cautions
Cardiac adverse reactions in elderly and cardiovascular disease, incl. atrial fibrillation — start lower dose
Do not use oral thyroid hormone to treat myxedema coma
Acute adrenal crisis if adrenal insufficiency — give glucocorticoids first
Pediatric: pseudotumor cerebri, craniosynostosis; hypersensitivity to inactive ingredients
Pregnancy Post-marketing experience reports no increased rate of birth defects/miscarriage; do not discontinue; requirements may increase — monitor and adjust.
Lactation Present in human milk; insufficient information on effects on the breastfed infant.